Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
Federal Trade Commission
Johnson and Johnson

Generated: November 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,470,506

« Back to Dashboard

Which drugs does patent 7,470,506 protect, and when does it expire?

Patent 7,470,506 protects PREZISTA and PREZCOBIX and is included in three NDAs. There has been one Paragraph IV challenge on Prezista.

Protection for PREZISTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,470,506

Title:Fitness assay and associated methods
Abstract:The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R.sup.1, R.sup.2, R.sup.3, R.sup.5 or R.sup.6 is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH.sub.2, O, S, SO, SO.sub.2, amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO.sub.2; m is from 0 to 6; R.sup.4 is OH, .dbd.O (keto), NH.sub.2, or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO.sub.2. Optionally, R.sup.5 and R.sup.6, together with the N--W bond of formula (I), comprises a macrocyclic ring.
Inventor(s): Erickson; John W. (Frederick, MD), Gulnik; Sergei V. (Frederick, MD), Mitsuya; Hiroaki (Chevy Chase, MD), Ghosh; Arun K. (River Forest, IL)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (Urbana, IL) Board of Trustees of the University of Illinois (
Application Number:09/720,276
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-004Dec 18, 2008RXYesNo► Subscribe► SubscribeY
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-005Dec 18, 2008RXYesNo► Subscribe► SubscribeY
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-001Jun 23, 2006DISCNYesNo► Subscribe► SubscribeY
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-003Oct 21, 2008DISCNYesNo► Subscribe► SubscribeY
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-002Feb 25, 2008RXYesNo► Subscribe► SubscribeY
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-006Nov 9, 2012RXYesYes► Subscribe► SubscribeY
Janssen Prods
darunavir ethanolate
SUSPENSION;ORAL202895-001Dec 16, 2011RXYesYes► Subscribe► SubscribeY
Janssen Prods
cobicistat; darunavir ethanolate
TABLET;ORAL205395-001Jan 29, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,470,506

PCT Information
PCT FiledJune 23, 1999PCT Application Number:PCT/US99/14119
PCT Publication Date:December 29, 1999PCT Publication Number: WO99/67417

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School
Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus